Regulus Therapeutics (RGLS) shares were down 21% in recent trading Wednesday even after the company said that a portion of subjects benefited from farabursen in an early-stage study.
Interim results from the fourth cohort of subjects enrolled in the company's phase 1b study of farabursen found that patients with autosomal dominant polycystic kidney disease, or ADPKD, responded to the treatment.
The interim data was based on the first 14 subjects of the cohort who also saw a "notable reduction" in height-adjusted total kidney volume growth rate, the company said.
Additionally, all 26 subjects in the cohort demonstrated that farabursen was well tolerated, according to Regulus.
Meanwhile, the company said it had successfully concluded a meeting with the US Food and Drug Administration in December, reaching an agreement on the design of a phase 3 trial of farabursen.
Price: 0.92, Change: -0.25, Percent Change: -21.03
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.